论文部分内容阅读
研究了以产生抗人小细胞肺癌相关抗原和ＣＤ３双特异性抗体（Ｂｉｓｐｅｃｉｆｉｃａｎｔｉｂｏｄｙ）的杂交杂交瘤（Ｈｙｂｒｉｄ－ｈｙｂｒｉｄｏｍａ）的方法及双特异性抗体的性质。两个具有不同表型（ＨＡＴ敏感／Ｎｅｏ拮抗和ＨＡＴ拮抗／Ｎｅｏ敏感）杂交瘤细胞系，经常规方法进行融合。最后选出７个分泌双特异性抗体的杂交。杂交瘤细胞系并对其中一个克隆系细胞进行了测示研究。结果表明，该克隆系细胞培养上清能有效增强ＬＡＫ细胞对靶瘤细胞的杀伤活性，表明其具有临床应用前景。
A method to produce Hybrid-hybridoma that is resistant to small cell lung cancer-associated antigen and CD3 bispecific antibody and the properties of the bispecific antibody were studied. Two hybridoma cell lines with different phenotypes (HAT-sensitive / Neo-antagonistic and HAT-antagonistic / Neo-sensitive) were fused by conventional methods. Finally, seven hybrids secreting bispecific antibodies were selected. Hybridoma cell line and one of the clonal line cells were tested. The results showed that the clonal cell culture supernatant can effectively enhance the killing activity of LAK cells to target tumor cells, indicating that it has a clinical application prospect.